Member Info for subush79

RP2020

This is not because of RNS as price is down because of coordinated attack by greedy shorters, though that is allowed by system. All RNS released recently are fantastic. We just waiting for C/T to start and funding announce. Let’s see if trader/shorter wins when funding announce or it is LTHs. CAR T, CBR and CDX- count those product candidates and current M/K.

Next placing would be £8 (minimum) + 40% warrants with exercise price of £24 in 12 months. My guess.

My concern is vague interview, which creats confusion and difficult to trust company position. Traders get benefit from this kind of situation and company destroy their reputation.

They should have done short, conscise, clear and to the point interview. What LTH and potential investors wanted IMO is-

trial start plan (now their excuses is for disclosure of financial interest). Not even clear whose financial interest?

Funding plan- either they want funding by placing shares or involvement of big pharma or investors in different form.

CBR status- to some extent they gave some information. However, it would be helpful how they going to fund for further process of CBR?

What is the status of CDX?

I think VS or BoD need to come with good plan within this week otherwise I can see S/P going down towards penny status IMO.

What LTH and potent

JHFH

Are you sure those block of sells today were not folrward sold by placings? We talked same in the past but they did placing in 2p and again at 1p.

That is your explanation MarcoBerlin.

Why they couldn’t clarify those details in the interview?

That’s why I said they are not capable to present multi million pound company.

They said there are 25 patients ready but they need to complete formalities.

However, the way they presented information is very poor. It doesn’t seem right that they are running multi million company with life saving projects.

HEMO board needs to rectify this. This company will fly to moon if things presented correctly and honestly IMO.

Pumpky

Do you live in social benefit? I have not seen any meaningful post by you except personal attack. Sorry as I have to ask this to understand what your position is?

Only problem with this company now is traders and shorter. They just want tonplay and make couple of quids for their lunch and dinner.,Differed shares are incentives for long term investors when company is successful in their product. That would be massive dividend to real investors. I am not here for gaining couple of pounds from my investment. When you want good return then you need to take risk as well. No risk no reward. Let's see where this share would be in few weeks time.

I am voting yes and no confusion about consolidation snd deferred share at all.

It is worth reposting Marcos’ post:

Hg-ct-1

I would like to briefly share my thoughts on this. This is not the first company I have invested in that aims to treat AML. My last company spent approximately $400 million on all studies from Phase 1 to the end of Phase 3. After phase 1 which showed successful data, big investors like BlackRock etc came in very quickly. Large institutional investors ultimately paid hundreds of millions of dollars in exchange for shares. But they only do this if their financial existence is secured. For this purpose, for example, there must be additional shares in the background that could be issued to finance the future! Currently, the limit for issuing shares has almost been reached and they could only be brought onto the market for a small amount of money. The decision to swap shares 400:1 ultimately has no impact on existing shareholders, as the share capital remains intact. Ultimately, this is just the psychology of what is happening. The bottom line is that you are currently making the decision for phases 2 and 3, where you need a lot of money. The step was foreseeable and does not come as a complete surprise. The timing is of course unfortunate. I can only say one thing to every investor, with AML everything depends on the results. No matter what happens now and whether there will be dilutive share issues. If hg-ct-1 is successful, the potential market value will be in the billions per year! Despite all the understandable anger that the price is going in the wrong direction, it's just a snapshot. At the end there will be a settlement and the starting signal has only just been given!

I vote Yes as this is the way we should support to company to get achieve their objectives. Only shorter and traders are interested to gain in short term and they have no interest for company success.

I been here since last 5 years and I know how this company is progressing. Every company go through this type of transition during initial phase. Look for Google during their establishment phase .

That’s why Vote Yes is the right decision.

Thanks Diggit but you know we have been waiting sooo long and we are almost on very final stage of result good/bad. In addition there are other product candidates that are also good value for investors. I do understand frustration but we need to praise if company is doing very good in meagre resources. Patience is very important for genuine investors.

You are right Pumpky. Have you read RNS that where they going to do trial? Have you checked their track record and their reputation? Do you think it is that tough to find patient for trial by MD Anderson Centre? Please be realistic and don't try to create negativity. If you are genuine investor then you shouldn't come with negativity everytime. Therae are many positives to come and I am very hopeful that HEMO wil bring good return to all genuine investor. Good luck everyone. Just hold for gold.

Hey Stu,

How many times you have said good bye and good luck. Can you please stay away if you are honestly saying good bye? If you are just playing and trying to feed negativity for your ego then I am enjoying to read your post just last sentence.

DID YOU KNOW?

In 2023, the FDA approved 43 new cancer drugs for public, clinical use. MD Anderson contributed to the development of 25 of those — nearly 60%.

They should have submitted financial details by 28th May and results should be announced by Tuesday 4th June. Next week can be a decisive week for CLON. Finger and toes crossed.

HEMO need to update regarding partnership with big pharma and biodefence programme as well to make sure that they are genuinely working on that part and hope to get that update soon.

Hemogenyx Pharmaceuticals (HEMO.L*): Update Note - 21 May 2024

Entering the clinic with HEMO-CAR-T

· Clinical hold lifted for HEMO-CAR-T: The US Food and Drug Administration (FDA) has consented to Hemogenyx proceeding with its Phase I clinical study of HEMO-CAR-T.

HEMO-CAR-T Phase 1 trial set to begin this year: Hemogenyx is planning a Phase 1/2 trial using HEMO-CAR-T in patients with relapsed or refractory (r/r) Acute Myeloid Leukaemia (AML). The study should generate safety data and provide a preliminary indication of efficacy.

Fundraise supporting the initiation of the clinical trial: Earlier this year, the Company completed a placing to raise $4m to support clinical development of HEMO-CAR-T.

Cell therapies remain an area of industry interest: There continue to be a number of transactions concerning cell therapy assets at an early clinical stage. The generation of clinical data on HEMO-CAR-T should support potential partnership discussions.

Continued progress on CBR: Researchers at the Company have identified a protein which could be used to develop an off-the-shelf therapy with activity against a wide range of viral diseases. Should CBR generate positive data, we expect interest from biodefence programmes

Implied fair value of £90m based on an evaluation of the Company’s peers.

Updated on Hemo Twitter as well about recent progress and implied fair value of £90m based on an evaluation of the company's peers.

Let's see how market reacts as MMs' always look for weak hands and wanted their share for this big potential project. Already traded about 1.2b shares, which is about 20% of total issued shares. It might reach 30-40% by end of the day. Massive potential I guess as there are 10 companies, which submitted for all 7 sites. If Clon can get EU back up then no need to worry to get this project.

Just hold for next 15 working days and result will be published. All company need to submit their next phase document within 10 business days, which is by end of 28th of May and result will be published within 5 business working days, which is 4th of June.